Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2021

May 12, 2021

SELL
$158.92 - $221.61 $8.25 Million - $11.5 Million
-51,920 Closed
0 $0
Q4 2020

Feb 10, 2021

BUY
$162.05 - $240.27 $188,788 - $279,914
1,165 Added 2.3%
51,920 $11.4 Million
Q3 2020

Nov 05, 2020

BUY
$113.26 - $167.27 $5.75 Million - $8.49 Million
50,755 New
50,755 $8.43 Million

Others Institutions Holding MRTX

About Mirati Therapeutics, Inc.


  • Ticker MRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,609,800
  • Description
  • Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...
More about MRTX
Track This Portfolio

Track Lisanti Capital Growth, LLC Portfolio

Follow Lisanti Capital Growth, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lisanti Capital Growth, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lisanti Capital Growth, LLC with notifications on news.